OM PHARMA enters a new partnership agreement for Broncho-Vaxom in China with UCB Trading shanghai
April 24th, 2008

Meyrin/Geneva. OM PHARMA has signed an important new partnership agreement with UCB Trading shanghai for the distribution and promotion of Broncho-Vaxom® in Mainland China. Broncho-Vaxom®, OM PHARMA’s lead biotechnology product, is indicated for the prevention of respiratory tract infections by boosting the body’s own immune defences against pathogenic micro-organisms.

After its merger with Schwarz Pharma, UCB counts today a strong field workforce of 350 people in China. Promising results are expected from the combined promotion of Broncho-Vaxom® and Xyzal® (levocetirizine - an oral antihistaminic drug for allergies) in the world’s most populous country and fastest growing major economy.

Top of the page